Mirum Pharmaceuticals (MIRM) PT Raised to $95 at Baird

Baird analyst Brian Skorney raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $95.00 (from $88.00) while maintaining a Outperform rating.

The analyst commented: "Positive on preliminary results, raising PT to $95. Mirum's preliminary 4Q25 and FY25 sales numbers came in ahead of expectations, including the upper end of their guidance, and management apparently sees durability in the performance with guidance for continued strong growth in 2026. Mirum also has a slate of catalysts in 2026, with the Phase 2b VISTAS trial reading out in 2H26, topline data from brelivotug in HDV in 2H26, and the EXPAND trial of Livmarli accelerated to a 4Q26 readout. We're raising our PT to $95 on commercial strength."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Mosaic sets pricing for tender offers on up to $1.4B in debt